Open AccessCharacterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01
Author(s) -
Beatriz Vera,
Naiara Martínez-Vélez,
Enric Xipell,
Arlet Acanda de la Rocha,
Ana Patiño-García,
Javier S. Castresana,
Marisol González-Huárriz,
Manel Cascalló,
Ramón Alemany,
Marta M. Alonso
Publication year - 2016
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0147211
Subject(s) - oncolytic virus , glioma , oncolytic adenovirus , in vivo , cancer research , medicine , oncology , biology , tumor cells , microbiology and biotechnology
Despite the recent advances in the development of antitumor therapies, the prognosis for patients with malignant gliomas remains dismal. Therapy with tumor-selective viruses is emerging as a treatment option for this devastating disease. In this study we characterize the anti-glioma effect of VCN-01, an improved hyaluronidase-armed pRB-pathway-selective oncolytic adenovirus that has proven safe and effective in the treatment of several solid tumors. VCN-01 displayed a significant cytotoxic effect on glioma cells in vitro . In vivo , in two different orthotopic glioma models, a single intra-tumoral administration of VCN-01 increased overall survival significantly and led to long-term survivors free of disease.